Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Street View: Brokerages flag margin headwinds for India's Divi's Laboratories

Changes reporter's name; no changes to text

May 25 (Reuters) - ** Divi's Laboratories DIVI.NS posted 13.4% Y/Y rise in Q4 consol profit, on strong performance in the custom synthesis and nutraceuticals segments

** Shares of pharmaceuticals co down 1.6%

SUB-HEAD

** Jefferies ("buy," PT: 7,950 rupees) management was

uncertain regarding margin outlook as dedicated capacities are being built up using technology owned by innovator and it is yet to receive commercial quantities

** BOB Capital Markets ("hold," PT: 7,500 rupees) says margin headwinds to persist in near term

** Ambit Capital ("sell," PT: 6,230 rupees) cuts EBITDA estimates by ~4% citing near-term gross margin pressure and change in revenue mix

** Dolat Capital ("reduce," PT: 6,942 rupees) says co faced difficulty in sourcing raw materials during March quarter due to the West Asia war but managed through domestic suppliers

** Systematix ("hold," PT: 6,539 rupees) says drop

in gross margin in Q4 was despite a favorable currency movement and favorable business mix

 (Reporting by Vijay Malkar in Bengaluru)

 ((VijayDattaram.Malkar@thomsonreuters.com; Mobile: +91 8097833031;))

Recent news on Divi's Laboratories

See all news